Physician profile
Tatum Karos
NPI 1811537632
$4,805.76
in general payments reported to CMS, 2019-2025
16 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,374 · 2023: $1,171 · 2024: $1,156 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,432.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $812.55 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $792.25 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $644.16 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $638.65 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Indivior INC. | $514.49 | 2022-2025 | Sublocade, Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $386.05 | 2022-2025 | Caplyta |
| Abbvie INC. | $221.34 | 2022 | |
| Neurocrine Biosciences, INC. | $187.49 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $154.67 | 2022-2024 | Fanapt, Hetlioz |
| Braeburn INC. | $132.34 | 2023-2025 | Brixadi |
| Lundbeck LLC | $87.83 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $71.42 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $66.22 | 2022 | |
| Almatica Pharma LLC | $41.46 | 2022 | |
| Axsome Therapeutics, INC. | $32.22 | 2025 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $22.62 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tatum Karos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.